May 2022 on Pestell: Dr. Pestell and the Compan
Post# of 148087
Dr. Pestell and the Company are also exploring ways in which Dr. Pestell can reengage with the Company to help realize leronlimab’s full potential in oncology. CytoDyn regrets Dr. Pestell’s departure from the Company and the subsequent public statements made by its former CEO about Dr. Pestell.
__
To me, if his reengagement is also directly affiliating to Cytodyn, reporting to Max, then this collab is a serious signal of "something"..... : )
I think we'll see additional collab teams on a couple other indications too.
" step by step "